A Study of the Efficacy and Safety of RWJ-333369 as add-on Therapy in the Treatment of Partial Onset Seizures.

• Status: Completed
• Trial end date: 2007-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to demonstrate that RWJ-333369 is safe and effective as add-on treatment of partial onset seizures.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SK Life Science; SK Life Science, Inc.

Criteria

Inclusion Criteria:

• Male or Female, 16 year or older

• Clinical diagnosis of focal epilepsy for at least 1 year

• History of poor response to at least 1 anti-epileptic drug in the past

• Current treatment with 1 or 2 anti-epileptic drugs

• Should have at least 3 seizures per month

Exclusion Criteria:

• Generalized epilepsy

• Cannot count your seizures

• Unstable medical disease, such as a recent heart attack or uncontrolled diabetes

• Major psychiatric illness

• Recent drug or alcohol abuse

• Unable to swallow pills